Docoh
Loading...

GNPX Genprex

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company's lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca's Tagrisso®) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone.

GNPX stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

13 Aug 21
25 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Genprex earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 44.24M 44.24M 44.24M 44.24M 44.24M
Cash burn (monthly) (positive/no burn) 1.33M 1.54M 988.94K 1.19M
Cash used (since last report) n/a 5.11M 5.93M 3.8M 4.6M
Cash remaining n/a 39.13M 38.32M 40.44M 39.65M
Runway (months of cash) n/a 29.4 24.9 40.9 33.2

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
27 Sep 21 Mark Stanley Berger Stock Option Common Stock Grant Acquire A No No 2.85 550,000 1.57M 550,000
27 Sep 21 Hermant Kumar Stock Option Common Stock Grant Acquire A No No 2.85 400,000 1.14M 400,000
24 Jun 21 Brent M Longnecker Stock Option Common Stock Grant Acquire A No No 3.55 32,376 114.93K 32,376

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

12.2% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 61 73 -16.4%
Opened positions 13 20 -35.0%
Closed positions 25 4 +525.0%
Increased positions 13 22 -40.9%
Reduced positions 22 16 +37.5%
13F shares
Current Prev Q Change
Total value 20.39M 58.68M -65.3%
Total shares 5.82M 8.22M -29.2%
Total puts 203.7K 371.2K -45.1%
Total calls 192.6K 246.1K -21.7%
Total put/call ratio 1.1 1.5 -29.9%
Largest owners
Shares Value Change
Vanguard 1.85M $6.2M -0.6%
Renaissance Technologies 629.52K $2.11M +105.7%
BLK Blackrock 548.57K $1.84M -72.6%
Millennium Management 481.5K $1.61M +279.6%
Geode Capital Management 358.63K $1.2M -34.4%
MS Morgan Stanley 196.95K $661K +857.6%
Susquehanna International 188.4K $631K -42.9%
Ergoteles 133K $446K NEW
UBS UBS Group AG - Registered Shares 113.57K $380K +0.3%
First Trust Advisors 108.23K $363K -3.3%
Largest transactions
Shares Bought/sold Change
BLK Blackrock 548.57K -1.45M -72.6%
STT State Street 101.02K -454.35K -81.8%
Nuveen Asset Management 0 -400.93K EXIT
Millennium Management 481.5K +354.67K +279.6%
Renaissance Technologies 629.52K +323.52K +105.7%
NTRS Northern Trust 82.84K -252.3K -75.3%
Geode Capital Management 358.63K -188.29K -34.4%
MS Morgan Stanley 196.95K +176.38K +857.6%
Susquehanna International 188.4K -141.49K -42.9%
Ergoteles 133K +133K NEW

Financial report summary

?
Management Discussion
  • Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
  • This Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) contains certain forward-looking statements. Historical results may not indicate future performance. Our forward-looking statements reflect our current views about future events, are based on assumptions and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those contemplated by these statements. Factors that may cause differences between actual results and those contemplated by forward- looking statements include, but are not limited to, those discussed in “Risk Factors.” We undertake no obligation to publicly update or revise any forward-looking statements, including any changes that might result from any facts, events, or circumstances after the date hereof that may bear upon forward-looking statements. Furthermore, we cannot guarantee future results, events, levels of activity, performance, or achievements.
  • We are a clinical stage gene therapy company focused on developing life-changing treatments for cancer and diabetes. Our lead cancer drug candidate, REQORSA™ Immunogene therapy drug (sometimes referred to as GPX-001), is being developed to treat NSCLC. The active agent in REQORSA is a TUSC2 gene expressing plasmid that is encapsulated in a DOTAP cholesterol nanoparticle.  TUSC2 is a tumor suppressor gene which has both tumor killing (via apoptosis) and immunomodulatory effects. We utilize our novel proprietary ONCOPREX® Nanoparticle Delivery System to deliver the TUSC2 gene expressing plasmid to cancer cells. The TUSC2 gene is one of a series of genes whose therapeutic use is covered by our exclusive worldwide licenses from MD Anderson. 
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: accrual, acquisition, addressed, adequately, announced, backlog, broad, brought, carefully, chain, commence, confirmed, delta, demand, depression, disrupt, disrupted, disruption, distribution, divert, dosing, elongation, evolved, Excluding, face, flat, immaterial, impede, interrupt, interrupted, larger, local, long, movement, NaN, nonperformance, notified, ongoing, paused, protocol, PTO, quarantine, raw, recession, recruitment, retention, site, situation, spread, supply, usable, usage, variant, voluntary, widely, workforce
Removed: degree, deteriorate, driven, execution, expectation, inadequate, location, month, occupy, planning, population, slightly, unregistered, variable